# Preoperative Downstaging of Extraperitoneal T3 Rectal Cancer: XELOXRT Versus XELACRT. A Multicenter, Phase III Study

> **NCT01653301** · PHASE3 · UNKNOWN · sponsor: **Catholic University of the Sacred Heart** · enrollment: 616 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** XELAC RT
- **DRUG:** XELOX RT

## Key facts

- **NCT ID:** NCT01653301
- **Lead sponsor:** Catholic University of the Sacred Heart
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-10
- **Primary completion:** 2012-12
- **Final completion:** —
- **Target enrollment:** 616 (ESTIMATED)
- **Last updated:** 2012-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01653301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01653301, "Preoperative Downstaging of Extraperitoneal T3 Rectal Cancer: XELOXRT Versus XELACRT. A Multicenter, Phase III Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01653301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*